CMPS COMPASS Corp: Koefisien utang jangka dawa marang modal

COMPASS Pathways plc (CMPS) is developing innovative psilocybin-based depression treatments, leveraging patent protection to establish premium pricing within its niche. However, business expansion is hindered by the requirement for direct physician involvement in therapy, which limits process automation. Drug logistics are strictly regulated, and the 0.67 metric complements the analysis, which this chart's market price visualizes.

The stability of synthetic compound supply chains for clinics confirms the operational resilience of COMPASS Pathways plc (CMPS), which, combined with the long-term debt financial leverage ratio on GURU.Markets, allows for an assessment of indebtedness risk. The ratio of liabilities with a maturity of over one year to equity determines the company's dependence on external financing, where low values guarantee survival during market shocks.